Investment Analysts’ Weekly Ratings Updates for Genmab A/S (GMAB)

Several brokerages have updated their recommendations and price targets on shares of Genmab A/S (NASDAQ: GMAB) in the last few weeks:

  • 11/13/2026 – Genmab A/S had its price target lowered by Morgan Stanley from $57.00 to $56.00. They now have an “equal weight” rating on the stock.
  • 11/9/2026 – Genmab A/S was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
  • 10/30/2026 – Genmab A/S had its price target raised by Morgan Stanley from $42.00 to $57.00. They now have an “equal weight” rating on the stock.
  • 10/30/2026 – Genmab A/S had its price target raised by Guggenheim from $58.00 to $80.00. They now have a “buy” rating on the stock.
  • 10/29/2026 – Genmab A/S had its “buy” rating reaffirmed by Truist Financial. They now have a $67.00 price target on the stock, up from $45.00.
  • 10/29/2026 – Genmab A/S had its price target raised by HC Wainwright from $50.00 to $70.00. They now have a “buy” rating on the stock.
  • 10/26/2026 – Genmab A/S had its price target raised by TD Cowen from $43.00 to $52.00. They now have a “buy” rating on the stock.
  • 10/26/2026 – Genmab A/S was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”.
  • 10/20/2026 – Genmab A/S was given a new $42.00 price target by Morgan Stanley.
  • 10/7/2026 – Genmab A/S had its price target raised by Truist Financial from $40.00 to $45.00. They now have a “buy” rating on the stock.
  • 10/7/2026 – Genmab A/S had its price target raised by HC Wainwright from $40.00 to $50.00. They now have a “buy” rating on the stock.
  • 10/5/2026 – Genmab A/S had its price target raised by Guggenheim from $45.00 to $54.00. They now have a “buy” rating on the stock.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $50.97 on Thursday. The business has a fifty day moving average price of $42.24 and a 200-day moving average price of $31.88. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.45 and a quick ratio of 2.43. The company has a market capitalization of $31.81 billion, a PE ratio of 43.56, a PEG ratio of 2.09 and a beta of 0.73. Genmab A/S Sponsored ADR has a 1-year low of $23.62 and a 1-year high of $59.97.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20. Genmab A/S had a net margin of 16.97% and a return on equity of 13.67%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion. As a group, equities analysts expect that Genmab A/S Sponsored ADR will post 1.28 EPS for the current fiscal year.

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Read More

Receive News & Ratings for Genmab A/S Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.